Verastem, Inc. is a clinical biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The Company also develops companion diagnostics. The Company has technology to create a stable population of cancer stem cells that it uses to screen for and identify small molecule compounds that target cancer stem cells. The Company�s advanced programs target the Focal Adhesion Kinase (FAK), and the PI3K/mTOR signaling pathways. The Company�s lead FAK inhibitor, VS-6063, is in Phase 1/1b testing in ovarian cancer. The Company�s solution is to discover and develop an oncology therapeutics targeting CSCs along with companion diagnostics. In February 2014, the Company announced that it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals.